Canada markets closed

PFE Sep 2022 45.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.3700-0.0500 (-11.90%)
As of 03:56PM EDT. Market open.
Full screen
Previous Close0.4200
Open0.4100
Bid0.3600
Ask0.3900
Strike45.00
Expire Date2022-09-16
Day's Range0.3600 - 0.4500
Contract RangeN/A
Volume273
Open Interest18.76k
  • Editor's Pick
    Yahoo Finance Video

    Axios sells itself to Cox Enterprises, Carlyle CEO to step down, CVS and Pfizer look to expand

    Yahoo Finance's Julie Hyman breaks down leading business headlines today regarding M&A activity and leadership changes.

  • Business Wire

    Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

    NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.

  • Motley Fool

    Why BioNTech Was a Sickly Stock on Monday

    BioNTech (NASDAQ: BNTX), the out-of-nowhere German biotech that shot to prominence with the coronavirus vaccine it developed with Pfizer (NYSE: PFE), wasn't having a great Monday. For its second quarter, BioNTech's revenue was just under 3.2 billion euros, or $3.3 billion, while its net profit stood at 1.67 billion euros. In that frame, BioNTech's top line was a bit over 5.3 billion euros, and it netted almost 2.79 billion euros in profit.